Diabetic Gastroparesis - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463985 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Diabetic Gastroparesis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H2 2019, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Phase I stages are 1, 3, 6 and 1 respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Gastroparesis - Overview

Diabetic Gastroparesis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Diabetic Gastroparesis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Gastroparesis - Companies Involved in Therapeutics Development

AlfaSigma SpA

Allergan Plc

Bird Rock Bio Inc

Censa Pharmaceuticals Inc

CinRx Pharma LLC

ETX Pharma Inc

Evoke Pharma Inc

Johnson & Johnson

Takeda Pharmaceutical Co Ltd

Vanda Pharmaceuticals Inc

Diabetic Gastroparesis - Drug Profiles

CIN-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CNSA-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metoclopramide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nimacimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prucalopride succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relamorelin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

renzapride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-906 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tradipitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

velusetrag - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diabetic Gastroparesis - Dormant Projects

Diabetic Gastroparesis - Discontinued Products

Diabetic Gastroparesis - Product Development Milestones

Featured News & Press Releases

May 17, 2019: Allergan expands PLEDGE Clinical Research Program in Diabetic Gastroparesis

Dec 03, 2018: Vanda announces positive phase II study results for Tradipitant in patients with gastroparesis

Oct 08, 2018: Allergan to present data on Relamorelin at ACG 2018

May 15, 2018: EndoLogic Announces FDA Accepts Cardiac Safety Trial for Renzapride in Patients with Gastroparesis

Aug 09, 2017: EndoLogic Announces Feedback from Positive FDA Meeting for Renzapride in Diabetic Gastroparesis

May 03, 2017: EndoLogic Announces Scheduling of pre-IND Meeting with FDA to Discuss Renzapride in Diabetic Gastroparesis

May 01, 2017: Allergan to Present Data on Relamorelin at Digestive Disease Week 2017

Dec 06, 2016: Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis

Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

Apr 08, 2015: Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis

May 06, 2014: Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis

May 20, 2013: Rhythm Announces Phase Ib Results For Ghrelin Prokinetic RM-131 For Gastroparesis In Patients With Type 1 Diabetes

Oct 22, 2012: Rhythm Announces Positive Phase I Results For Ghrelin Prokinetic RM-131 For Treatment Of Diabetic Gastroparesis

Jun 06, 2012: Rhythm Initiates Phase II Clinical Trial Of Ghrelin Prokinetic RM-131 For Diabetic Gastroparesis

May 22, 2012: Rhythm Announces Phase Ib Results Of RM-131 For Diabetic Gastroparesis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463985 | GMDHC11433IDB

Number of Pages

73

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
22-03-2017

$2,000 USD

Published by Global Markets Direct
22-03-2017

$2,000 USD

Published by Global Markets Direct
28-02-2017

$2,000 USD

Published by Global Markets Direct
28-02-2017

$2,000 USD

Published by Global Markets Direct
23-11-2016

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Diabetic Gastroparesis - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.